Gottipamula Sanjay, Sundarrajan Sudarson, Moorthy Aditya, Padmanabhan Sriram, N Sridhar K
Sri Research for Tissue Engineering Pvt. Ltd, Shankara Research Centre, Rangadore Memorial Hospital, Bangalore, India.
Cancyte Research Pvt. Ltd, Rangadore Memorial Hospital, Bangalore, India.
J Maxillofac Oral Surg. 2018 Jun;17(2):254-259. doi: 10.1007/s12663-017-1056-1. Epub 2017 Nov 17.
Oral submucosal fibrosis (OSMF) is a chronic debilitating fibrotic disease of the oral cavity and is a serious health hazard in south Asia and, increasingly, the rest of the world. The molecular basis behind various treatment modalities to treat OSMF still remains unclear. In this study, we have investigated the in vitro ability of the buccal mucosal cells to reduce the proliferation of the fibroblasts of the fibrotic area in co-culture of cells and also at the molecular levels to reduce the level of connective tissue growth factor (CTGF) in the OSMF fibroblasts (SMF-F).
The study compares isolation, morphological and proliferation kinetics of SMF-F and BMF cells with and without co-culturing with BMEs. In addition, we have compared the mRNA expression levels of CTGF in SMF-F co-cultured BME and non-co-cultured SMF-F cells using validated real-time quantitative PCR (RT-qPCR) method.
The basic morphological characteristics of SMF-F were similar to BMF, but the former cells had higher proliferation rate in early passages compared to late passage state. We also observed that the CTGF expression levels in SMF-F under co-culture conditions of BME were consistently and significantly downregulated in all four different SMF-F-derived cells from four different patients.
Rapid proliferation and collagen synthesis in SMF-F as against BMF cells are the factors that confirm the innate nature of fibrosis fibroblasts (SMF-F). Further, the CTGF expression level in SMF-F was significantly suppressed by BME in co-culture conditions against controls (BMF). Considered together, this suggests that the cell therapeutic candidate of BME could be used in treating OSMF.
口腔黏膜下纤维化(OSMF)是一种口腔慢性致残性纤维化疾病,在南亚以及世界其他地区对健康构成严重危害。治疗OSMF的各种治疗方式背后的分子基础仍不清楚。在本研究中,我们研究了颊黏膜细胞在细胞共培养中降低纤维化区域成纤维细胞增殖的体外能力,以及在分子水平上降低OSMF成纤维细胞(SMF-F)中结缔组织生长因子(CTGF)水平的能力。
本研究比较了SMF-F和BMF细胞在与BME共培养和不共培养情况下的分离、形态学和增殖动力学。此外,我们使用经过验证的实时定量PCR(RT-qPCR)方法比较了共培养BME的SMF-F和未共培养的SMF-F细胞中CTGF的mRNA表达水平。
SMF-F的基本形态特征与BMF相似,但与传代后期相比,前体细胞在传代早期具有更高的增殖率。我们还观察到,在来自四名不同患者的所有四种不同的SMF-F衍生细胞中,BME共培养条件下SMF-F中的CTGF表达水平持续且显著下调。
与BMF细胞相比,SMF-F中快速增殖和胶原蛋白合成是证实纤维化成纤维细胞(SMF-F)固有性质的因素。此外,在共培养条件下,与对照(BMF)相比,BME显著抑制了SMF-F中的CTGF表达水平。综合考虑,这表明BME的细胞治疗候选物可用于治疗OSMF。